Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)

Date

08 Oct 2016

Session

CNS tumours

Presenters

Anna Sophie Berghoff

Citation

Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367

Authors

A.S. Berghoff1, J. Furtner2, G. Widhalm3, B. Gatterbauer3, U. Dieckmann4, P. Birner5, R. Bartsch1, C. Zielinski1, V. Schöpf6, M. Preusser1

Author affiliations

  • 1 Department Of Medicine1, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 2 Department Of Biomedical Imaging And Image-guided Therapy, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 3 Department Of Neurosurgery, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 4 Department Of Radiotherapy, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 5 Department Of Pathology, Medizinische Universitaet Wien (Medical University of Vienna), 1090 - Vienna/AT
  • 6 Institute Of Psychology, Medical University Graz, 8010 - Graz/AT
More

Resources

Background

Sarcopenia has been described as objectively measurable parameter indicating frailty and adverse prognosis in several cancer types. We thus hypothesized that TMT may serve as surrogate marker of frailty.

Methods

189 BC patients (luminal A: 45/189 (23.8%); HER2: 75/189 (39.7%); triple negative: 35/189 (18.5%); unknown subtype: 34/189 (18.0%), all female with a median age of 54 years (range 30-85) and newly diagnosed BM were identified from a BM database. Clinical characteristics including survival times were retrieved from chart review. Diagnosis specific graded prognostic assessment (DS-GPA) was calculated based on clinical characteristics. Baseline TMT at diagnosis of BM was measured in MRI (axial plane of isovoxel (1x1x1mm), T1 – weighted images) at diagnosis of BM.

Results

Median TMT was 5.4 mm (range 1.65 – 10.50 mm) and showed no correlation with age (correlation coefficient -0.341; p 

Conclusions

TMT, which can serve as a surrogate parameter of sarcopenia, is an independent predictor of survival in patients with newly diagnosed BC BM. TMT is easily and reproducibly assessable in routine MR images and may help to better define frail patient populations and may thus facilitate patient management by supporting patient selection for therapeutic measures or clinical trials.

Clinical trial identification

Legal entity responsible for the study

Medical University of Vienna

Funding

Medical University of Vienna

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings